Literature DB >> 8065164

Serum laminin P1 in idiopathic myelofibrosis and related diseases.

H Hasselbalch1, P Junker.   

Abstract

The serum concentration of laminin P1 antigen was determined in 32 patients with various myeloproliferative disorders, including 19 patients with idiopathic myelofibrosis. The serum concentration of the aminoterminal propeptide of type III procollagen (PIIINP) was measured concomitantly in 27 patients. Serial laminin measurements were carried out in 25 patients. The median serum laminin concentration in patients with acute disease, i.e. acute myelofibrosis and patients in a transforming disease phase was significantly higher (1.58 U/ml; range 1.15-2.07) as compared with patients with chronic disease (1.02 U/ml; range 0.75-1.76; p = 0.012) and healthy control subjects (1.13 U/ml; range 0.75-1.67; p = 0.00015). In individual patients serum laminin covariated closely with serum PIIINP, the leucocyte count and LDH. The median serum laminin concentration in patients with a huge spleen was significantly lower than in the patient group with a normal spleen size/previous splenectomy. Pronounced splenomegaly was particularly prevalent in patients with chronic disease implicating splenic enlargement as a significant extrahepatic site of laminin uptake/degradation in myeloproliferative disorders.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8065164     DOI: 10.1016/0145-2126(94)90044-2

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

1.  Serum laminin and basic fibroblast growth factor concentrations in patients with complicated Plasmodium falciparum malaria.

Authors:  H Burgmann; S Looareesuwan; C Viravan; S Vanijanonta; K Zedwitz-Liebenstein; H Vorbach; W Graninger
Journal:  J Clin Immunol       Date:  1996-09       Impact factor: 8.317

2.  Increased serum laminin and angiogenin concentrations in patients with peripheral arterial occlusive disease.

Authors:  H Burgmann; U Hollenstein; T Maca; K Zedwitz-Liebenstein; F Thalhammer; R Koppensteiner; H Ehringer; W Graninger
Journal:  J Clin Pathol       Date:  1996-06       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.